Ultimate First Article Approval Checklist For A New Supplier
The first commercial batch from a new intermediate supplier is not a formality. Here is the checklist, the five approval outcomes, and how to log the call.
Orforglipron intermediates;(S)-1-(4-F-2-Me-indazol-5-yl)-3-(2-(4-F-3,5-diMe-phenyl)-4-Me-tetrahydropyrazolo[4,3-c]pyridin-3-yl)-imidazol-2-one
CAS: 2212022-56-3
Chemical Formula: C₂₆H₂₅F₂N₇O
Molecular Weight: 489.52
Availability: R&D; Commercialization
⬤ CAS No.2212022-56-3
⬤ Our Packaging type:
20kg barrel;5kg barrel;1kg bag;500g bag ; Customized Packaging
| Product Name | (S)-1-(4-fluoro-2-methyl-2H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-1H-imidazol-2(3H)-one |
| CAS.No | 2212022-56-3 |
| Molecular Formula | C₂₆H₂₅F₂N₇O |
| Molecular Weight | 489.52 |
| Related Categories | This compound is often used in drug development, especially as a key intermediate in the synthesis of Orforglipron molecules |
| Appearance | Usually white to off-white solid |
| Boiling Point | About 650°C |
| Density | 1.45±0.1 g/cm³(Predicted) |
| Acidity coefficient (pKa) | 8.39±0.40(Predicted) |
| Precautions | This product is a research chemical and cannot be used directly on the human body. |
| Personal Protection | This product is a chemical synthesis product and may be irritating. Protective equipment (such as gloves, goggles, and lab coats) must be worn when handling it. |
| Storage Conditions | Store sealed and dry at -20°C, away from light and moisture. Use as soon as possible after opening. Remaining samples must be resealed and labeled. |
| R&D purposes | This product is a high-purity pharmaceutical intermediate, mainly used in the following research and development areas, as a key intermediate for the treatment of anabolic diseases (such as diabetes, obesity), especially for the construction of non-peptide GLP-1 receptor agonists (such as Orforglipron analogs) |
| Application | Used as key intermediates to synthesize molecules with specific biological activities, such as drugs for metabolic diseases such as diabetes and obesity (such as orforglipron analogs) |
Reliable Global Partner
“Tianming Pharmaceutical has redefined reliability for us. Their ability to deliver high-potency APIs and intermediates under tight deadlines—is unmatched. The team’s transparency in documentation and proactive updates make them a stress-free partner. A true backbone for our operations!”
March 18, 2024
Outstanding Technical Guidance
“Few suppliers align so perfectly with EU GMP requirements. Tianming’s commitment to audit-ready quality systems, batch traceability, and purity consistency has streamlined our production processes. Their diligence eliminates regulatory risks—a rare advantage in today’s market.”
February 15, 2024
Beyond Supplier, A Solutions Partner
“Tianming’s technical team doesn’t just deliver materials—they solve problems. When we faced stability challenges with a niche compound, their scientists proposed a tailored purity adjustment that saved our project timeline. Their agility transforms obstacles into opportunities.”
June 15, 2024
Strategic Growth Ally
“Over 5+ years, Tianming has consistently adapted to our evolving needs—whether scaling volumes or supporting custom synthesis projects. Their ethical pricing models and long-term vision make them more than a vendor; they’re integral to our competitive edge.”
April 27, 2024
The first commercial batch from a new intermediate supplier is not a formality. Here is the checklist, the five approval outcomes, and how to log the call.
A buyer-side decision tree for handling an intermediate supplier change notice — what to accept, contest, or reject, and how to log the call.
A supplier discontinuation is a deadline, not just bad news. The questions to ask in writing, the last-time-buy calculation, and the files to collect in time.
Manufacturer and supplier of pharmaceutical APIs and intermediates. Contact us for technical support and sourcing solutions.